Vidalenc P, Morel J L, Mironneau J, Hugues M
Centre National de la Recherche Scientifique, ESA5017, Physiopathologie et Pharmacologie Vasculaire, Faculté de Pharmacie, Université Victor Segalen (Bordeaux 2), 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.
Biochem J. 1998 Apr 1;331 ( Pt 1)(Pt 1):177-84. doi: 10.1042/bj3310177.
Mapacalcine is a small protein (Mr=19041) composed of two homologous chains purified from the marine sponge Cliona vastifica. Recently, we demonstrated that it was able to specifically block a Ca2+ channel which could not be related to already described channels on mouse intestinal myocytes. This Ca2+ current was insensitive to the known peptidic and organic calcium channel blockers. Mapacalcine was ineffective on T-type and L-type Ca2+ currents present on rat portal vein myocytes [Morel, Drobecq, Sautière, Tartar, Mironneau, Qar, Lavie, and Hugues (1997) Mol. Pharmacol. 51, 1042-1052]. We report here the preparation and purification of a monoiodo-derivative of mapa-calcine which retains its biological properties. Binding parameters of mapacalcine to its receptors have been characterized on mouse intestinal membranes. It binds to its receptors with a Kd=0. 8 nM, and a maximal binding capacity of 171 fmol/mg of protein on membrane preparations. Our data show that we have prepared a tool that is usable for pharmacological studies of a receptor associated with a new type of calcium channel for which no ligand was available until now.
马帕卡辛是一种小蛋白(分子量 = 19041),由从海洋海绵巨大穿贝海绵中纯化得到的两条同源链组成。最近,我们证明它能够特异性阻断一种钙通道,该通道与小鼠肠肌细胞上已描述的通道无关。这种钙电流对已知的肽类和有机钙通道阻滞剂不敏感。马帕卡辛对大鼠门静脉肌细胞上的T型和L型钙电流无效[莫雷尔、德罗贝克、索蒂埃、塔尔塔尔、米罗诺、卡尔、拉维以及于格斯(1997年)《分子药理学》51卷,第1042 - 1052页]。我们在此报告保留其生物学特性的马帕卡辛单碘衍生物的制备与纯化。已在小鼠肠膜上对马帕卡辛与其受体的结合参数进行了表征。它与受体结合的解离常数Kd = 0.8纳摩尔,在膜制剂上每毫克蛋白质的最大结合容量为171飞摩尔。我们的数据表明,我们制备了一种工具,可用于对与新型钙通道相关的受体进行药理学研究,而迄今为止尚无该受体的配体。